INCY · Incyte Corporation
$113.752026-07-21Sector: Healthcare; Industry: Biotechnology; Sub-Industry: Biotechnology
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Bull
$233
+105.0% vs market
Base · active
$180
+57.8% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($169 · $233) Analysts Range ($90 · $140) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2024.Q1 | $3.7B | — | 22.1% | 26.8% | $598MM | −$170MM | $428MM | 7.6% | — | 8.7% | $6.9B | $2.89 | — |
| 2024.Q4 | $3.7B | 0.0% | 22.1% | 45.0% | $449MM | −$156MM | $293MM | 8.2% | — | 6.7% | $6.6B | $2.89 | — |
| 2025.Q1 | $4.2B | 14.8% | 3.0% | 45.0% | $69MM | −$405MM | −$336MM | 8.0% | — | 0.8% | $9.8B | $0.16 | — |
| 2025.Q4 | $4.2B | 0.0% | 3.0% | 22.7% | $98MM | −$946MM | −$848MM | 8.1% | — | 1.0% | $10.1B | $0.16 | — |
| 2026.Q1 | $5.4B | 26.4% | 33.7% | 19.3% | $1.5B | −$962MM | $496MM | 7.8% | — | 15.9% | $8.2B | $6.92 | 13.0 |
| italics below = DCF projection · 10yr Rev CAGR: 6.5% |
| 2027.Q1 | $5.8B | +7.6% | 33.6% | 19.4% | $1.6B | −$645MM | $917MM | 7.7% | $851MM | 18.3% | $8.9B | $6.06 | 18.8 |
| 2028.Q1 | $6.3B | +8.8% | 36.2% | 19.4% | $1.8B | −$833MM | $997MM | 7.8% | $859MM | 19.7% | $9.7B | $7.10 | 16.0 |
| 2029.Q1 | $6.8B | +8.2% | 34.5% | 19.5% | $1.9B | −$877MM | $1.0B | 7.9% | $802MM | 18.6% | $10.6B | $7.31 | 15.6 |
| 2030.Q1 | $7.3B | +7.6% | 22.7% | 19.6% | $1.3B | −$916MM | $419MM | 8.0% | $310MM | 12.1% | $11.5B | $5.18 | 22.0 |
| 2031.Q1 | $7.8B | +7.0% | 22.7% | 19.6% | $1.4B | −$947MM | $481MM | 8.1% | $329MM | 11.9% | $12.4B | $5.54 | 20.5 |
|
| Term. Yr+ | $10.5B | 4.1% | 34.4% | 20.0% | $2.9B | −$906MM | $2.0B | 8.6% | $20.2B | 13.1% | — | — | — |
Active scenario IV: $180 (+57.8% vs market)